
    
      This study will enroll subjects with severe pulmonary hypertension until a maximum of 30
      patients have undergone implantation with the Occlutech® AFR device. Enrolment will be
      devided in 2 phases.

      Phase 1: At least 15 adult patients with age ≥ 18 years will be enrolled. Phase 2: Patients
      with age ≥ 6 years will be enrolled until a maximum of 30 patients is reached.
    
  